Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Efruxifermin by Akero Therapeutics for Liver Cirrhosis: Likelihood of Approval
Efruxifermin is under clinical development by Akero Therapeutics and currently in Phase III for Liver Cirrhosis. According to GlobalData, Phase...
Efruxifermin by Akero Therapeutics for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
Efruxifermin is under clinical development by Akero Therapeutics and currently in Phase III for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to...
Efruxifermin by Akero Therapeutics for Type 2 Diabetes: Likelihood of Approval
Efruxifermin is under clinical development by Akero Therapeutics and currently in Phase II for Type 2 Diabetes. According to GlobalData,...
Efruxifermin by Akero Therapeutics for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Likelihood of Approval
Efruxifermin is under clinical development by Akero Therapeutics and currently in Phase III for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)....